HRS 2020: Boston Scientific’s Emblem S-ICD Proves Safe And Effective In ‘Sickest Population’
Executive Summary
Results of two studies presented at the Heart Rhythm Society Scientific Sessions support the subcutaneous implantable cardioverter defibrillator as an alternative to ICDs with transvenous leads.
You may also be interested in...
Boston Scientific Advances First ‘Modular’ Cardiac Rhythm Management System
The MODULAR ATP clinical trial has begun to enroll patients to evaluate the safety, performance and effectiveness of Boston Scientific’s mCRM modular therapy system, which includes the Emblem MRI S-ICD and the Empower MPS leadless pacemaker.
Death, Serious Injuries Lead To Class I Recall For Boston Scientific’s Emblem Electrode
The US FDA affixed its highest-risk classification to a recall of the electrode, which is part of the company’s Emblem S-ICD system.
UNTOUCHED Trial Shows Low Complication Rate With Boston Scientific’s Emblem S-ICD
Procedural outcome data of the UNTOUCHED trial of the Emblem subcutaneous implantable cardioverter defibrillator show low perioperative complication rates and high conversion efficacy of induced ventricular fibrillation in a high-risk patient population.